Health and Fitness Health and Fitness
Tue, May 18, 2010
[ 01:05 PM ] - Market Wire
TomoTherapy to Present at Two Upcoming Investment Conferences
[ 01:05 PM ] - Market Wire
Illumina Receives FDA 510(k) Clearance for VeraCo .. for Factor V (Leiden) and Factor II (Prothrombin)
[ 01:00 PM ] - Market Wire
TomoTherapy EMEA User Education Symposium Brings .. ether Users Throughout Europe and the Middle East
[ 12:58 PM ] - Market Wire
Millipore Corporation named to Globe 100
[ 11:09 AM ] - Market Wire
Cardiovascular Systems to Present at the 2010 Cit .. Investment Research Global Health Care Conference
[ 11:00 AM ] - Market Wire
Aetna Wins Two National ClearMark Awards from the Center for Plain Language
[ 10:26 AM ] - Market Wire
Covidien introduceert hechtingsapparaat SILS voor geavanceerde laparoscopie
[ 10:00 AM ] - Market Wire
Oncolytics Biotech(R) Inc. Announces Publication .. linical Trial Results in Clinical Cancer Research
[ 09:56 AM ] - Market Wire
Sierra Geothermal Makes Discovery at Alum and Reports Q1 2010 Financials
[ 09:16 AM ] - Market Wire
Vitro Announces Open Letter to Its Shareholders: Current Results and Future Prospects
[ 08:45 AM ] - Market Wire
Nautic Partners Sells Medegen to CareFusion
[ 08:25 AM ] - Market Wire
JCR and Hill-Rom Name Nurse Safety Scholar-in-Residence
[ 08:00 AM ] - Market Wire
UnitedHealth Group invierte casi US$ 3,4 millones .. mejorar el acceso a la atencin de la salud en la
[ 07:24 AM ] - Market Wire
CORRECTINGand REPLACINGTargacept Announces Participation in Upcoming Conferences
[ 07:21 AM ] - Market Wire
New Leaf Brands Announces 2010 First Quarter Financial Results
[ 07:12 AM ] - Market Wire
CardioNet, Inc. to Present at the Citi 2010 Global Health Care Conference
[ 07:00 AM ] - Market Wire
Canarc Shareholder Update First Quarter Review and Second Quarter Outlook, 2010
[ 07:00 AM ] - Market Wire
XenoPort to Present at the 2010 Citi Health Care Conference
[ 06:45 AM ] - Market Wire
Cellceutix Files Foreign Patent Application in PC .. er Key Countries for Its Flagship Cancer Compound
[ 06:36 AM ] - Market Wire
Rosetta Genomics Identifies 49 Novel microRNAs wi .. l Molecular Biomarkers and Drug Target Candidates
[ 06:30 AM ] - Market Wire
Adamis Pharmaceuticals Announces Plans to Develop Its First Prostate Drug Candidate
[ 06:15 AM ] - Market Wire
Cytokinetics Announces Presentation of Non-Clinic .. le Contractility Program at the American Thoracic
[ 06:15 AM ] - Market Wire
Zynex Announces Q1 2010 Financial Results
[ 06:00 AM ] - Market Wire
Health Management Associates Chooses PatientKeepe .. rized Physician Order Entry as Key Component of S
[ 05:55 AM ] - Market Wire
Targacept Announces Participation in Upcoming Conferences
[ 05:55 AM ] - Market Wire
Kendall Law Group Investigating Psychiatric Solutions Merger for Shareholders
[ 05:41 AM ] - Market Wire
Forest Laboratories, Inc. Announces New Share Repurchase Program
[ 05:30 AM ] - Market Wire
Aoxing Pharmaceutical Company Reports Third Quarter 2010 Financial and Operational Results
[ 05:30 AM ] - Market Wire
Merc Intersects 15.85 Grams Gold Per Tonne Over 7.0 Metres at BIF Island
[ 05:15 AM ] - Market Wire
Incyte to Present at the Citi Investment Research 2010 Global Health Care Conference

Incyte to Present at the Citi Investment Research 2010 Global Health Care Conference


Published on 2010-05-18 05:25:25 - Market Wire
  Print publication without navigation


WILMINGTON, Del.--([ BUSINESS WIRE ])--Incyte Corporation (Nasdaq:INCY) announced today it will present at the Citi Investment Research 2010 Global Health Care Conference on Wednesday, May 26, 2010 at 4:30 p.m. ET.

The presentation will be webcast live and can be accessed at [ www.incyte.com ] under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 30 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation. Incyte's most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, visit the Company's web site at [ www.incyte.com ].

Contributing Sources